$195M AbbVie Expansion To Boost Domestic API Production For Neuroscience, Immunology, And Oncology Drugs
AbbVie invests $195M to expand U.S. API production in North Chicago, strengthening domestic drug manufacturing capacity.
Breaking News
Aug 15, 2025
Simantini Singh Deo

AbbVie has announced a $195 million investment to expand its manufacturing site in North Chicago, Illinois, enhancing domestic production of active pharmaceutical ingredients (APIs). This move is part of the company’s broader plan to invest over $10 billion in the U.S., strengthening innovation and increasing manufacturing capacity for critical medicines.
"Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs," said Robert A. Michael, chairman and chief executive officer, AbbVie. "This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."
The new API facility will advance AbbVie’s chemical synthesis capabilities in the U.S., supporting the production of current and future treatments in neuroscience, immunology, and oncology. API manufacturing is a complex process involving the creation of the active components that deliver therapeutic effects in medicines.
"AbbVie's decision to expand its manufacturing footprint in Illinois is a testament to our state's world-class workforce, infrastructure, cutting-edge research institutions, and location that keeps businesses connected to the nation and the world," said Governor JB Pritzker. "As a global leader in pharmaceuticals, AbbVie's investment in Illinois bolsters our world-class biomanufacturing ecosystem and creates jobs while it innovates next-generation medicines."
Construction on the new facility is set to begin in fall 2025, with operations expected to start in 2027. The expansion will add to AbbVie’s existing U.S. manufacturing network, which employs over 6,000 people across 11 sites, and will also support thousands of supplier jobs nationwide. AbbVie remains committed to its Illinois headquarters, home to more than 11,000 employees working on innovative medicines for patients worldwide.